Table 2 Comparison of pathological characteristics between groups
All patients (N = 256) | Without remission (N = 103) | Remission (N = 153) | P value | |
|---|---|---|---|---|
Morphological staging, no.(%) | 0.108 | |||
I+ II | 232 (90.6) | 85 (82.6) | 147 (96.1) | |
III + IV | 24 (9.4) | 18 (17.5) | 6 (3.9) | |
Lesions of FSGS, no. (%) | 28 (10.9) | 6 (5.8) | 22 (14.4) | 0.032* |
Crescent formation, no. (%) | 34 (13.3) | 16 (15.5) | 18 (11.8) | 0.384 |
Tubular atrophy, no. (%) | 0.382 | |||
T0 | 31 (12.1) | 17 (16.5) | 14 (9.2) | |
T1 | 178 (69.5) | 59 (57.3) | 119 (77.8) | |
T2 | 43 (16.8) | 26 (25.2) | 17 (11.1) | |
T3 | 4 (1.6) | 1 (1.0) | 3 (2) | |
IgG4-dominant deposition, no. (%) | 182 (71.1) | 74 (71.8) | 108 (70.6) | 0.828 |
IgA deposition, no. (%) | 39 (15.2) | 19 (18.4) | 20 (13.1) | 0.241 |
IgM deposition, no. (%) | 66 (25.8) | 31 (30.1) | 35 (22.9) | 0.195 |
C3 deposition, no. (%) | 222 (86.7) | 88 (85.4) | 134 (87.6) | 0.620 |
C1q deposition, no. (%) | 86 (33.6) | 33 (32) | 53 (34.6) | 0.666 |
PLA2R deposition, no. (%) | 199 (77.7) | 76 (73.8) | 123 (80.4) | 0.213 |